Neurotoxicity associated with adenine arabinoside monophosphate in the treatment of chronic hepatitis B virus infection.
Thirty-one patients with chronic HBV infection were randomized to receive a short or long course of ARA-AMP. Fifteen completed a 4 week course of treatment and 16 completed longer courses varying from 7 to 12 weeks. Eighteen patients did not experience any neurological side effects. Six patients had myalgia. This was not associated with any neurological deficit. Seven patients developed a sensory neuropathy with distressing pain and dysesthesiae in the feet and abnormalities in nerve conduction. The development of neurotoxicity was related to a long duration of treatment and a correspondingly higher total dose but there was no association with the severity of liver disease.
D000293:Adolescent; D000328:Adult; D001088:Arabinonucleotides / Q000009:adverse effects*; D002908:Chronic Disease; D005260:Female; D006509:Hepatitis B / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009135:Muscular Diseases / Q000139:chemically induced; D009422:Nervous System Diseases / Q000139:chemically induced*; D010146:Pain / Q000139:chemically induced; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced; D011446:Prospective Studies; D012306:Risk; D001084:Vidarabine Phosphate / Q000009:adverse effects* / Q000627:therapeutic use
D001088:Arabinonucleotides; D001084:Vidarabine Phosphate